Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ViroPharma gets rights to use Halozyme's Enhanze platform to deliver Cinryze; terminated

Executive Summary

ViroPharma Inc.'s ViroPharma SPRL division (developing compounds for life-threatening diseases) has licensed exclusive global rights to Halozyme Therapeutics Inc.’s (uses enzymes to deliver drugs) Enhanze drug delivery platform, which contains the recombinant human hyaluronidase enzyme rHuPH20. ViroPharma will use the technology to create a single subcutaneous form of Cinryze (C1 esterase inhibitor (human)) for hereditary angioedema (HAE) as well as three other orphan conditions.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register